Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06854393 · ClinicalTrials.gov registry record · Phase 2
Lacripep for Corneal Wound Healing Study
A Phase 2 study of Corneal Epithelial Wound Healing, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 1
- Study location
NCT06854393: Recruiting Phase 2 study of Corneal Epithelial Wound Healing, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
NCT06854393 is a Phase 2 study of Corneal Epithelial Wound Healing that is actively recruiting participants, run by Henry M. Jackson Foundation for the Advancement of Military Medicine. The registered enrollment target is 88 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06854393, a Phase 2 study of Corneal Epithelial Wound Healing, is actively recruiting participants, sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).
Primary Outcome
To determine the efficacy of Lacripep for corneal wound healing, epithelial thickness will be be measured using optical coherence tomography (OCT). OCT is a non-invasive imaging technique that uses light waves to create detailed images of tissue structures.
Conditions Studied
Interventions
- DRUG 0.00025% Lacripep ophthalmic solution and Placebo
Study Locations (1)
Virginia
- Alexander T. Augusta Military Medical Center - Fort Belvoir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2025-05-23 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT06854393 shows while recruiting
NCT06854393 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Corneal Epithelial Wound Healing appearing as the primary indexed condition, and to 1 intervention - of which 0.00025% Lacripep ophthalmic solution and Placebo is the first listed.
NCT06854393 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06854393 about?
NCT06854393 is a clinical study titled "Lacripep for Corneal Wound Healing Study". The objective of this study is to evaluate the safety and effectiveness of Lacripep as a therapy for superficial corneal injury repair after Photorefractive keratectomy (PRK).
What is the current status of trial NCT06854393?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2025-05-23. Estimated completion is 2027-09.
What conditions does trial NCT06854393 study?
This clinical trial studies the following conditions: Corneal Epithelial Wound Healing.
What interventions are being tested in trial NCT06854393?
The interventions under investigation include: 0.00025% Lacripep ophthalmic solution and Placebo (DRUG).
Who is sponsoring clinical trial NCT06854393?
This trial is sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06854393 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06854393's enrollment target sits among peer trials
88 803rd of 2000 higher than 1,192 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI